0.30%| Prev Close: | 98.54 |
|---|---|
| Open: | 98.52 |
| Bid: | 98.08 x 100 |
| Ask: | 98.12 x 100 |
| 1y Target Est: | 113.54 |
| Beta: | 0.64 |
| Next Earnings Date: | N/A |
| Day's Range: | 97.71 - 99.32 |
|---|---|
| 52wk Range: | 81.28 - 116.45 |
| Volume: | 1,813,316 |
| Avg Vol (3m): | 1,799,210 |
| Market Cap: | 28.96B |
| P/E (ttm): | 34.07 |
| EPS (ttm): | 2.88 |
| Div & Yield: | 0.20 (0.20%) |
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- 4 Stocks Going Ex-Dividend Tomorrow: PGH, NTI, MAT, AGNat TheStreet(Mon, 20 May)
- Allergan Stock To Go Ex-dividend Tomorrow (AGN)at TheStreet(Mon, 20 May)
- Allergan About To Put More Money In Your Pocket (AGN)at Forbes(Fri, 17 May)
- Finny Kuruvilla, Portfolio Manager of the Eventide Gilead Fund, Interviews with The Wall Street Transcript: Investing in Health Care InnovationWall Street Transcript(Fri, 17 May)
- AGN, LLY, BIIB, CELG And AMGN, Pushing Health Care Sector Downwardat TheStreet(Fri, 17 May)
- Why This Stock's Crash is a Buying Opportunityat Motley Fool(Wed, 15 May)
- ALLERGAN INC FinancialsEDGAR Online Financials(Sun, 12 May)
- Regeneron Pharma raises sales forecast for EyleaAP(Sat, 4 May)
- Allergan slides, Regeneron surges on eye drug newsAP(Thu, 2 May)
- Allergan shares fall on delay of eye drug studyAP(Thu, 2 May)
Press Releases
- FDA Advisory Committee Unanimously Recommends JUVÉDERM VOLUMA™ XC as a Safe and Effective Treatment Option for Cheek Augmentation to Correct Age-Related Volume Deficit in the Mid-FaceBusiness Wire(Fri, 3 May)
- Allergan Reports First Quarter 2013 Operating ResultsBusiness Wire(Wed, 1 May)
- Allergan Announces Death of Stephen J. Ryan, M.D.Business Wire(Tue, 30 Apr)